Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants.

ABSTRACT: The ubiquitin proteasome system (UPS) has garnered much attention due to its potential for the development of therapeutics. Following a successful clinical application of general proteasome inhibitors much effort has been devoted to targeting individual UPS components including E3 enzymes and deubiquitinases that control specificity of ubiquitination. Our group has developed a novel approach for targeting the UPS proteins using engineered ubiquitin variants (Ubvs). These drug-like proteins can serve as valuable tools to study biological function of UPS components and assist in the development of small molecules for clinical use. In this review, we summarize studies of Ubvs targeting members of three major families, including deubiquitinases, HECT E3 ligases, and CRL E3 ligases. In particul

SUBMITTER: Gorelik M 

PROVIDER: S-EPMC5434665 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature